Characterizing outcomes of ERBB2-amplified biliary tract cancer.

被引：0
|
作者：
Fox, Daniel Aaron
Haro-Silerio, Jaime
Bhamidipati, Deepak
Meric-Bernstam, Funda
Pant, Shubham
Ross, Jeffrey S.
Hu, Zishuo Ian
Koay, Eugene Jon
Ludmir, Ethan B.
Cao, Hop Sanderson Tran
Tzeng, Ching-Wei D.
Chun, Yun Shin
Vauthey, Jean-Nicolas
Newhook, Timothy E.
Metwalli, Zeyad
Habibollahi, Peiman
Cox, Veronica L.
Kang, Hyunseon
Javle, Milind M.
Lee, Sunyoung S.
机构：
[1] Baylor Coll Med, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA
[5] Fdn Med Inc, Cambridge, MA USA
[6] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Radiat Oncol, Houston, TX USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Intervent Radiol, Houston, TX USA
[10] Univ Texas MD Anderson Canc Ctr, Dept Abdominal Imaging, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-3532-2370-7650-2700; 283-237-2581-144; 298-4768-3691-2722; 261-7540; 613-4678-146; 261-492-9019; 6; 3; 2; 291; 176; 1; 38092-22447; 38092-34303; 38092-18909; 38092-30467; 38092-19994; 38092-32474; 38092-25821; 38092-20248; 38092-20245; 38092-20212; 38092-27371; 38092-33627; 38092-30779; 38092-27507; 38114-38096-7094; 38092-24862; 38092-23140; 38092-22449; 38092-18438; 14; 5; 4;
D O I：
10.1200/JCO.2024.42.3_suppl.492
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：492 / 492
页数：1
相关论文
共 50 条
  • [41] Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin
    Sergio Anastasi
    Gianluca Sala
    Chen Huiping
    Elisabetta Caprini
    Giandomenico Russo
    Stefano Iacovelli
    Fabiana Lucini
    Sigurdur Ingvarsson
    Oreste Segatto
    Oncogene, 2005, 24 : 4540 - 4548
  • [42] Outcomes in older patients with biliary tract cancer
    McNamara, Mairead G.
    Carino, Nicola de Liguori
    Kapacee, Zainul Abedin
    Lamarca, Angela
    Valle, Juan W.
    EJSO, 2021, 47 (03): : 569 - 575
  • [43] Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel
    Neil, Alexander J.
    Muto, Michael G.
    Kolin, David L.
    Konstantinopoulos, Panagiotis A.
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 48
  • [44] Germline pathogenic variants in a cohort of individuals with biliary tract cancer.
    Holter, Spring
    Borgida, Ayelet
    Beaudry, Felix
    Hildebrand, Maggie
    Dodd, Anna
    Wang, Xin
    Knox, Jennifer J.
    Vogel, Arndt
    Tsang, Erica S.
    Jang, Raymond Woo-Jun
    Elimova, Elena
    Moulton, Carol-Anne
    Reichman, Trevor
    Shwaartz, Chaya
    Sapisochin, Gonzalo
    Gallinger, Steven
    Grant, Robert C.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 559 - 559
  • [45] Co-Targeting PARP and ATR in biliary tract cancer.
    Nam, Ah Rong
    Jin, Mei Hua
    Oh, Kyoung-Seok
    Seo, Hye Rim
    Kim, Jae-Min
    Bang, Ju-Hee
    Yoon, Jeesun
    Kim, Tae-Yong
    Oh, Do-Youn
    CANCER RESEARCH, 2021, 81 (13)
  • [46] Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
    Valle, Juan
    Wasan, Harpreet
    Palmer, Daniel H.
    Cunningham, David
    Anthoney, Alan
    Maraveyas, Anthony
    Madhusudan, Srinivasan
    Iveson, Tim
    Hughes, Sharon
    Pereira, Stephen P.
    Roughton, Michael
    Bridgewater, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (14): : 1273 - 1281
  • [47] Second-line chemotherapy in patients with biliary tract cancer.
    Brandi, G.
    Di Girolamo, S.
    de Rosa, F.
    Corbelli, J.
    Agostini, V.
    Garajova, I.
    Longobardi, C.
    Paragona, M.
    Ercolani, G.
    Pinna, A. D.
    Biasco, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] ERBB2 oncogene is not amplified or overexpressed in prostate cancer
    Tammela, TL
    Savinainen, KJ
    Saramäki, OR
    Linja, MJ
    Bratt, O
    Isola, JJ
    Visakorpi, T
    JOURNAL OF UROLOGY, 2002, 167 (04): : 137 - 138
  • [49] Prognostic factors and scoring model for survival in advanced biliary tract cancer.
    Park, Hyung Soon
    Park, Ji Soo
    Roh, Yun Ho
    Moon, Jieun
    Yoon, Dong Sup
    Jeung, Hei-Cheul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [50] Genomics and translational precision oncology for 803 patients with biliary tract cancer.
    Lin, Jianzhen
    Yang, Xu
    Cao, Yinghao
    Li, Guangyu
    Zhao, Songhui
    Shi, Junping
    Pan, Jie
    Hu, Ke
    Zhao, Lin
    Guan, Mei
    Sang, Xinting
    Javle, Milind M.
    Wang, Kai
    Wang, Xiaoyue
    Zhao, Hai-Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345